Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD Total Liabilities
Everything the company owes to creditors and other parties.
Kodiak Sciences Inc.NASDAQ: KOD
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $196.84M at the end of Q3 FY2026, up 1.3% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at -5.6% a year.
Context
- Total liabilities amounted to 94.0% of total assets at the end of Q3 FY2026, up 4.9 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +1.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 194.15M USD
- Year-over-year change
- +4.8%
- 4-year CAGR
- -5.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 194.15M | +4.8% |
| FY2024 | 2024-12-31 | 185.29M | -13.3% |
| FY2023 | 2023-12-31 | 213.59M | -7.3% |
| FY2022 | 2022-12-31 | 230.46M | -4.3% |
| FY2021 | 2021-12-31 | 240.9M | — |
Total Liabilities vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1.3% is the 7th highest of 10, against a peer median of +7.8%.
- Total liabilities amounts to 94.0% of total assets for KOD, versus a peer median of 20.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $10.02B USD | +21.0% | +12.4% | 24.0% | |
| Jun 2026 | $7.42B USD | +1.2% | +22.9% | 53.5% | |
| Sep 2026 | $196.84M USD | +1.3% | -5.6% | 94.0% | |
| Mar 2026 | $150.96M USD | +7.8% | +10.5% | 20.6% | |
| Mar 2026 | $61.07M USD | +32.7% | +26.0% | 11.9% | |
| Mar 2026 | $57.75M USD | -10.0% | -11.7% | 20.0% | |
| Mar 2026 | $51.1M USD | +5.3% | +17.1% | 89.8% | |
| Mar 2026 | $50.89M USD | -1.3% | +36.9% | 232.4% | |
| Mar 2026 | CHF 47.2M CHF | +13.6% | -33.4% | 19.4% | |
BLTEBelite Bio, Inc | Jun 2026 | $14.95M USD | +129.2% | +53.7% | 1.9% |
| Peer median (excluding KOD) | — | +7.8% | +17.1% | 20.6% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 731.51M | 190.43M | 285.51M | 168.07M | 209.86M |
| Short-term Investments | 0 | 288.5M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.3M | 7.07M | 3.8M | 3.86M | 4.95M |
| Total Current Assets | 734.81M | 486.01M | 289.31M | 171.94M | 214.82M |
| Property, Plant & Equipment (Net) | 108.07M | 115.75M | 175.02M | 148.73M | 121.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 6.32M | 6.32M | 6.32M | 6.18M | 6.18M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 55.01M | 58.55M | 8.72M | 8.73M | 8.67M |
| Total Non-current Assets | 169.41M | 180.62M | 190.06M | 163.64M | 136.72M |
| Total Assets | 904.22M | 666.63M | 479.37M | 335.58M | 351.53M |
| Account Payables | 12.43M | 9.13M | 13.61M | 3.92M | 12.86M |
| Short-term Debt | 3.93M | 9.93M | 9.77M | 0 | 12.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 42.13M | 27.41M | 12.27M | 0 | 12.84M |
| Total Current Liabilities | 64.68M | 52.5M | 41.73M | 25.57M | 45.53M |
| Long-term Debt | 99.94M | 100M | 100M | 0 | 100M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 211K | 162K | 0 | 100M | 1.5M |
| Total Non-current Liabilities | 176.22M | 177.97M | 171.86M | 159.72M | 148.62M |
| Total Liabilities | 240.9M | 230.46M | 213.59M | 185.29M | 194.15M |
| Common Stock | 5K | 5K | 5K | 5K | 6K |
| Retained Earnings | (558.22M) | (892.04M) | (1.15B) | (1.33B) | (1.56B) |
| Accumulated OCI | 0 | (1.31M) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 663.32M | 436.17M | 265.78M | 150.29M | 157.38M |
| Total Debt | 179.94M | 187.73M | 181.63M | 70.35M | 159.18M |
| Net Debt | (551.57M) | (2.7M) | (103.88M) | (97.73M) | (50.68M) |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.